Sana Biotechnology Inc · Q1 2021 earnings

Briefing

Sana Biotechnology reported financial results and business highlights for the first quarter of 2021.

Sana Biotechnology reported a net loss of $180.6 million, or $1.52 per share, for the three months ended March 31, 2021. The company's cash, cash equivalents, and marketable securities totaled $981.9 million as of March 31, 2021.

• Presented key proof of concept data for multiple platforms at AACR 2021.
• Cash position was $981.9 million as of Q1 2021.
• Completed initial public offering in February 2021, issuing 27.0 million shares at $25.00 per share.
• Research and development expenses for the three months ended March 31, 2021 were $168.9 million.

Headline financials

Revenue & EPS history

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical development plans and timing expectations; updates at scientific and medical conferences; and the ability to make CAR T cells that evade the innate and adaptive immune system or that persist without immunosuppression.